New brain tumor drug under the microscope: does it improve daily life?
NCT ID NCT07240662
First seen Nov 21, 2025 · Last updated Apr 25, 2026 · Updated 21 times
Summary
This study follows 150 adults with a specific type of slow-growing brain tumor (grade 2 glioma with an IDH mutation) who are taking the drug vorasidenib after surgery. The main goal is to see how the drug affects their quality of life, including symptoms like seizures. Researchers will also track how well the drug controls the tumor and any side effects. This is an observational study, meaning doctors do not assign the treatment—they simply watch what happens in routine care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
RECRUITINGHeidelberg, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.